• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖严重程度与减重代谢手术患者中幽门螺杆菌根除的关系:一项事后分析。

Relationship between obesity severity and Helicobacter pylori eradication in patients undergoing bariatric and metabolic surgery: A post hoc analysis.

机构信息

Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina.

Clínica Monte Grande, Monte Grande, Buenos Aires, Argentina.

出版信息

Obes Surg. 2024 Oct;34(10):3790-3795. doi: 10.1007/s11695-024-07505-w. Epub 2024 Sep 12.

DOI:10.1007/s11695-024-07505-w
PMID:39264552
Abstract

BACKGROUND

The global prevalence of obesity is increasing and represents a major public health challenge. However, there is a paucity of data regarding Helicobacter pylori (H pylori) eradication in people with obesity. The aim of the study is to examine the influence of obesity degree on H. pylori eradication in patients undergoing bariatric and metabolic surgery.

METHODS

A post hoc analysis was conducted in a cohort of 204 adults patients (129 individuals diagnosed with obesity, 75 normal weight) H. pylori positive, included in two multicenter, prospective studies. Patients underwent a 14-day quadruple concomitant treatment, and H. pylori eradication was assessed using the 13C-urea breath test. The cohort was stratified according to body mass index (BMI), and statistical analyses were performed using chi-squared test, Kruskal-Wallis test, and logistic regression.

RESULTS

Eradication rates were significantly lower in patients with obesity compared with normal weight individuals (68.2% vs. 88.0%, OR 0.29, 95% CI 0.13-0.63, p < 0.01). Furthermore, within the population diagnosed with obesity, the degree of obesity correlated with decreased eradication rates, with class 3 (BMI 40.0-49.9) and class 4 (BMI ≥ 50.0) obesity showing the lowest rates (67% and 51%, with an OR 0.28 and 0.15 respectively, p < 0.01).

CONCLUSIONS

Our results indicate that obesity may influence H. pylori eradication, especially among severe obesity patients undergoing bariatric surgery, which could have implications for the development of ulcers and gastritis as well as the risk of gastric cancer. Tailored eradication strategies may be necessary to improve treatment efficacy in this population.

摘要

背景

全球肥胖患病率不断上升,成为主要的公共卫生挑战。然而,关于肥胖人群中幽门螺杆菌(H. pylori)根除的数据却很少。本研究旨在探讨肥胖程度对接受减重代谢手术患者 H. pylori 根除的影响。

方法

对两项多中心前瞻性研究中 204 例 H. pylori 阳性肥胖(129 例)和正常体重(75 例)成年人患者进行了一项事后分析。患者接受了为期 14 天的四联伴随治疗,使用 13C-尿素呼气试验评估 H. pylori 根除情况。根据体重指数(BMI)对队列进行分层,并使用卡方检验、Kruskal-Wallis 检验和逻辑回归进行统计分析。

结果

与正常体重患者相比,肥胖患者的根除率显著降低(68.2% vs. 88.0%,OR 0.29,95%CI 0.13-0.63,p<0.01)。此外,在肥胖患者人群中,肥胖程度与根除率降低相关,3 级(BMI 40.0-49.9)和 4 级(BMI≥50.0)肥胖的根除率最低(分别为 67%和 51%,OR 分别为 0.28 和 0.15,p<0.01)。

结论

我们的研究结果表明,肥胖可能会影响 H. pylori 的根除,尤其是在接受减重手术的严重肥胖患者中,这可能会导致溃疡和胃炎的发生风险增加,以及胃癌的风险增加。可能需要制定针对肥胖患者的个体化根除策略以提高该人群的治疗效果。

相似文献

1
Relationship between obesity severity and Helicobacter pylori eradication in patients undergoing bariatric and metabolic surgery: A post hoc analysis.肥胖严重程度与减重代谢手术患者中幽门螺杆菌根除的关系:一项事后分析。
Obes Surg. 2024 Oct;34(10):3790-3795. doi: 10.1007/s11695-024-07505-w. Epub 2024 Sep 12.
2
Eradication Rate of on the US-Mexico Border Using the Urea Breath Test.使用尿素呼气试验检测美墨边境地区的根除率。
South Med J. 2018 Jan;111(1):51-55. doi: 10.14423/SMJ.0000000000000747.
3
How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery?四联同步根除幽门螺杆菌疗法对接受胃旁路手术的肥胖患者的疗效如何?
Obes Surg. 2016 Jun;26(6):1163-6. doi: 10.1007/s11695-015-1920-3.
4
Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery.采用马斯特里赫特IV共识提出的一线和二线方案对接受胃旁路手术的肥胖患者进行幽门螺杆菌累积根除率的研究
Obes Surg. 2018 Mar;28(3):743-747. doi: 10.1007/s11695-017-2915-z.
5
The need for a patient-tailored Helicobacter pylori eradication protocol prior to bariatric surgery.在减肥手术前制定个性化幽门螺杆菌根除方案的必要性。
J Int Med Res. 2018 Jul;46(7):2696-2707. doi: 10.1177/0300060518769543. Epub 2018 Apr 24.
6
Tailored Helicobacter pylori eradication therapy in obese patients undergoing bariatric surgery.肥胖患者行减重手术后行个体化幽门螺杆菌根除治疗。
Rev Esp Enferm Dig. 2021 May;113(5):345-347. doi: 10.17235/reed.2020.7433/2020.
7
Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials.基于 Vonoprazan 的四联疗法根除消化性溃疡患者幽门螺杆菌的疗效和安全性:两项随机、双盲、双模拟、3 期临床试验的汇总分析。
Biol Pharm Bull. 2024;47(8):1405-1414. doi: 10.1248/bpb.b24-00011.
8
Can eradication rate of gastric Helicobacter pylori be improved by killing oral Helicobacter pylori?幽门螺杆菌能否通过杀灭口腔幽门螺杆菌来提高根除率?
World J Gastroenterol. 2013 Oct 21;19(39):6645-50. doi: 10.3748/wjg.v19.i39.6645.
9
Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.改良序贯疗法与四联疗法作为幽门螺杆菌感染患者的初始治疗方案比较
World J Gastroenterol. 2015 May 28;21(20):6310-6. doi: 10.3748/wjg.v21.i20.6310.
10
Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.韩国一线治疗失败后采用含莫西沙星疗法根除幽门螺杆菌
World J Gastroenterol. 2014 Jun 14;20(22):6932-8. doi: 10.3748/wjg.v20.i22.6932.

引用本文的文献

1
Does helicobacter pylori infection impact reflux symptoms after sleeve gastrectomy? A pilot study using patient reported outcome measures (PROMs).幽门螺杆菌感染会影响袖状胃切除术后的反流症状吗?一项使用患者报告结局指标(PROMs)的初步研究。
Surg Endosc. 2025 Jul 7. doi: 10.1007/s00464-025-11849-4.

本文引用的文献

1
Comprehensive guidance for antibiotic dosing in obese adults: 2022 update.肥胖成年人抗生素给药的综合指南:2022年更新版。
Pharmacotherapy. 2023 Mar;43(3):226-246. doi: 10.1002/phar.2769. Epub 2023 Feb 18.
2
2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery.2022年美国代谢与减重外科学会(ASMBS)和国际肥胖与代谢病外科联盟(IFSO):代谢与减重手术的适应证
Surg Obes Relat Dis. 2022 Dec;18(12):1345-1356. doi: 10.1016/j.soard.2022.08.013. Epub 2022 Oct 21.
3
The Current Role of Vonoprazan in Helicobacter pylori Treatment.
沃克(伏诺拉生)在幽门螺杆菌治疗中的当前作用。
Gastroenterology. 2022 Sep;163(3):572-574. doi: 10.1053/j.gastro.2022.06.076. Epub 2022 Jun 30.
4
Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.Vonoprazan 三联和双联疗法治疗美国和欧洲的幽门螺杆菌感染:随机临床试验。
Gastroenterology. 2022 Sep;163(3):608-619. doi: 10.1053/j.gastro.2022.05.055. Epub 2022 Jun 6.
5
Obesity: Epidemiology, Pathophysiology, and Therapeutics.肥胖症:流行病学、病理生理学与治疗学。
Front Endocrinol (Lausanne). 2021 Sep 6;12:706978. doi: 10.3389/fendo.2021.706978. eCollection 2021.
6
Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy.体质量对使用沃诺拉赞和阿莫西林双联疗法根除一线幽门螺杆菌成功率的影响。
Helicobacter. 2021 Apr;26(2):e12788. doi: 10.1111/hel.12788. Epub 2021 Feb 12.
7
Antimicrobial Dosing in Specific Populations and Novel Clinical Methodologies: Obesity.特殊人群的抗菌药物剂量和新的临床方法:肥胖。
Clin Pharmacol Ther. 2021 Apr;109(4):942-951. doi: 10.1002/cpt.2181. Epub 2021 Feb 28.
8
Tailored Helicobacter pylori eradication therapy in obese patients undergoing bariatric surgery.肥胖患者行减重手术后行个体化幽门螺杆菌根除治疗。
Rev Esp Enferm Dig. 2021 May;113(5):345-347. doi: 10.17235/reed.2020.7433/2020.
9
Current status of eradication and risk factors for eradication failure.根除现状及根除失败的危险因素。
World J Gastroenterol. 2020 Aug 28;26(32):4846-4856. doi: 10.3748/wjg.v26.i32.4846.
10
Benefits and Risks of Bariatric Surgery in Adults: A Review.成人减肥手术的获益与风险:综述
JAMA. 2020 Sep 1;324(9):879-887. doi: 10.1001/jama.2020.12567.